Goserelin acetate (ICI-118630 acetate) 是一种促性腺激素释放激素 (GnRH/LHRH) 十肽类似物，能作为GnRH激动剂。Goserelin acetate 可用于乳腺癌、上皮性卵巢癌和前列腺癌的研究。
| 生物活性 | Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as aGnRHagonist. Goserelin acetate can be used for the research of breastcancer, epithelial ovariancancerand prostatecancer[1][2]. |
| IC50& Target | |
体外研究
(In Vitro) | Goserelin (1 nM-1 mM; 48-72 hours) promotes EOC cell apoptosis[1].
Goserelin (100 μM; 24-72 hours) regulates the expression of human apoptosis-related genes in SKOV3-ip cells[1].
Goserelin (100 μM; 24-72 hours) promotes EOC cell apoptosis by upregulating FOXO1 through the PI3K/AKT signaling pathway[1].
Apoptosis Analysis[1] | Cell Line: | SKOV3 cells, SKOV3-ip cells, A2780 cells (human EOC cell lines) | | Concentration: | 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM, 1 mM | | Incubation Time: | 48 hours, 72 hours | | Result: | Significantly increased the total apoptosis rate of SKOV3-ip, SKOV3 and A2780 cells. |
Western Blot Analysis[1] | Cell Line: | SKOV3 cells, SKOV3-ip cells, A2780 cells (human EOC cell lines) | | Concentration: | 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM, 1 mM | | Incubation Time: | 48 hours, 72 hours | | Result: | The expression of cleaved-caspase-3 and cleaved-PARP were observably increased at 100 μM. |
RT-PCR[1] | Cell Line: | SKOV3-ip cells | | Concentration: | 100 μM | | Incubation Time: | 24 hours, 48 hours, 72 hours | | Result: | Expression of human apoptosis-related genes regulated |
|
体内研究
(In Vivo) | Goserelin (100 μg; s.c.; daily; for 19 days) significantly increases the proportion of apoptotic cells in the subcutaneous xenograft tumors[1].
| Animal Model: | Five-week-old specific-pathogen free (SPF) female nude mice (18-20 g), subcutaneous xenograft tumor model[1] | | Dosage: | 100 μg/mice | | Administration: | Subcutaneous injection, daily, for 19 days | | Result: | Significantly increased the proportion of apoptotic cells in the subcutaneous xenograft tumors |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Sealed storage, away from moisture | Powder | -80°C | 2 years | | -20°C | 1 year |
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| 溶解性数据 | In Vitro: H2O : 100 mg/mL(75.22 mM;Need ultrasonic) DMSO : ≥ 28 mg/mL(21.06 mM) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 0.7522 mL | 3.7609 mL | 7.5219 mL | | 5 mM | 0.1504 mL | 0.7522 mL | 1.5044 mL | | 10 mM | 0.0752 mL | 0.3761 mL | 0.7522 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 50 mg/mL (37.61 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (1.56 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (1.56 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (1.56 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (1.56 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 4. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: 2.08 mg/mL (1.56 mM); Clear solution; Need warming
此方案可获得 2.08 mg/mL (1.56 mM) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com